Clinical Nurse Specialist Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Sonia Vasil

Nurse Practitioner, Gerontology Cleveland, OH Clinical Nurse Specialist

NPI 1194191007 CMS profile 10664993

11100 Euclid Ave, Cleveland, OH 44106

Open in the dashboard

General payments

$989

42 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Sonia Vasil of Cleveland, OH is reported in the CMS Open Payments database as having received $989 across 42 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $372 15
2022 General $475 20
2021 General $142 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sonia Vasil
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Sonia Vasil were reported at $0. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Sonia Vasil Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $142 $133 $44–$396 $132
2022 $475 $142 $48–$452 $149
2023 $372 $158 $53–$482 $160
2024 $0 $171 $55–$533 $164
2025 $0 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. Novo Nordisk Inc $502 23 payments
  2. Horizon Therapeutics plc $121 1 payment
  3. Insulet Corporation $120 7 payments
  4. AstraZeneca Pharmaceuticals LP $95 1 payment
  5. Lilly USA, LLC $67 4 payments
  6. Radius Health, Inc. $17 1 payment
  7. Abbott Laboratories $14 1 payment
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $14 1 payment
  9. Bayer HealthCare Pharmaceuticals Inc. $13 1 payment
  10. Medtronic, Inc. $12 1 payment
  11. Other $11 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $989 42 payments
Products named General payments · program years 2021–2023
  1. RYBELSUS $362 19 payments
  2. Ozempic $336 19 payments
  3. TEPEZZA $121 1 payment
  4. Omnipod $120 7 payments
  5. FARXIGA $95 1 payment
  6. MOUNJARO $51 3 payments
  7. Saxenda $33 2 payments
  8. Tymlos $17 1 payment
  9. JARDIANCE $16 1 payment
  10. TRULICITY $15 1 payment
  11. Other $65 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

199

Median for Nurse Practitioner: 389

Drug cost

$125,830

Median for Nurse Practitioner: $21,885

Branded share of claims

72.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 32 $36,009
Ozempic Semaglutide Brand 18 $24,313
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 13 $23,801
Farxiga Dapagliflozin Propanediol Brand 12 $17,485
Jardiance Empagliflozin Brand 12 $15,792
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 11 $5,172
Nano 2nd Gen Pen Needle Pen Needle, Diabetic Brand 18 $1,515
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 11 $1,202
Levothyroxine Sodium Generic 21 $164
Metformin Hcl Generic 20 $156

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$1,118

Medicare's payments for the services billed

Medicare patients

45

Average age 70

Services billed

46

33 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 49%
Diabetes 38%
Cancer 31%
Depression 27%
Ischemic heart disease 24%
Osteoporosis 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

42 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record